References
- Else M, Dearden CE, Matutes E, . Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733–740.
- Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810–813.
- Thomas DA, O'Brien S, Bueso-Ramos C, . Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906–3911.
- Kreitman RJ, Stetler-Stevenson M, Margulies I, . Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983–2990.
- Lin TS, Ruppert AS, Johnson AJ, . Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012–6018.
- Arons E, Suntum T, Stetler-Stevenson M, . VH4-34 + hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687–4695.
- Forconi F, Sozzi E, Cencini E, . Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696–4702.
- Byrd JC, Shinn C, Waselenko JK, . Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804–3816.